Ruxolitinib is a major step forward for patients with chronic GVHD – where corticosteroids are inadequate
Results from abstract 77 presented at ASH. The oral JAK1-2 inhibitor ruxolitinib showed superior efficacy to best available treatment among patients with steroid-refractory or dependent chronic graft-versus-host disease (GVHD) in the phase 3 study REACH3.
